After a devastating battle of 9 September 1730, in Illinois, in which hundreds of warriors were killed and many women and children taken captive by French allies, Fox refugees took shelter with the Sac. This made them subject to French attack in turn. The Sac continued moving west to Iowa and Kansas. Keokuk and Black Hawk were two important leaders who arose among the Sauk. At first Keokuk accepted the loss of land as inevitable in the face of the vast numbers of white soldiers and settlers coming west. He tried to preserve tribal land and his people, and to keep the peace. Having failed to receive expected supplies from the Americans on credit, Black Hawk wanted to fight, saying his people were "forced into war by being deceived". Led by Black Hawk in 1832, the mainly Sac band resisted the continued loss of lands (in western Illinois, this time.) Their warfare with United States forces resulted in defeat at the hands of General Edmund P. Gaines in the Black Hawk War. Oklahoma history
About this time, one group of Sac moved into Missouri, and later to Kansas and Nebraska. In 1869, after the Civil War, the United States forced the larger group of Sac to move into a reservation in Indian Territory (now the state of Oklahoma). They merged with the Meskwaki as the federally recognized Sac and Fox Nation. (The United States had been making treaties with the two tribes together since their residency in the Midwest.)
Nineteen had microscopic residual disease post-surgery. Post-surgery, 6 of these patients were treated with high-dose corticosteroids; 5 with vinblastine + methotrexate chemotherapy; 3 with inhibitors of ALK; 2 with vinorelbine + low-dose cycloheximide or Ifosfamide-based chemotherapy; and 1 with cyclophosphamide + vinchristine + actinomycin D chemotherapy. Of these 19 patients, 4 had complete responses, 8 partial responses, 5 stable disease, and 2 progressive disease. Nine patients had macroscopic disease post-surgery; 5 of these patients received vincristine + methotrexate; 2 received ALK inhibitors; and 1 each received either high-dose corticosteroids or Ifosfamide-based chemotherapy. Of these 9 patients, none had complete responses; 6 had partial responses; 1 had steady disease; and 2 had progressive disease. There were no deaths among the 59 patients. The various drug regimens showed little differences in effectiveness although patients treated with ALK inhibitors trended to have longer response times. Another retrospective study evaluated the response of 17 patients (aged 22–46 years; median age 32 years) with advanced disease to Adriamycin-based chemotherapy regimens, i.e. Adriamycin alone, Adriamycin + Ifosfamide, or Adriamicin + other chemotherapy drugs. No patients had a complete response, 8 patients had partial responses, 4 patients had steady disease, and 5 patients had progressive disease. Progression-free survival and overall survival times for the group were 6.6 and 21.2 months, respectively.